AtaGenix Laboratories
AtaGenix Laboratories
Struggling with monoclonal antibody development? AtaGenix offers phage display custom services to streamline the process and deliver high-quality antibodies in less than 2 months. Our solutions address challenges like immunogenicity and complex humanization by providing direct access to human monoclonal antibodies. With the world’s first immune phage display library derived from human cancer patient donors and diverse naïve libraries featuring Fab, scFv, and VHH formats, we ensure unmatched diversity and efficiency.
AtaGenix guarantees at least three high-affinity binders tailored for applications such as ELISA, WB, or Flow Cytometry. Backed by extensive expertise and a proven track record, we are leaders in therapeutic, research, and diagnostic antibody development. Partner with us for innovative solutions and accelerated project success.
Rapid Turnaround
Get your antibodies in <2 months
Binding Guaranteed
At least 3 high-affinity binders
Proven Expertise
Benefit from our vast experience with over 500 successful phage display projects
A streamlined antibody development workflow, from immune library construction to functional validation. Designed for high diversity, precise screening, and rigorous testing, ensuring stable and effective antibody candidates for research, therapy, or diagnostics.
Milestone: Library diversity > 10⁹
Milestone: Selection of cross-reactive binders
Milestone: Stable and active antibody candidates
Milestone: Identification of lead candidates
AtaGenix provides highly specific anti-tauN368 monoclonal antibodies to support Alzheimer’s disease research using the hTau368 transgenic mouse model. These antibodies enable precise detection of truncated tau fragments in Western blot and immunofluorescence experiments, validating tau accumulation, phosphorylation, and associated cognitive deficits in the hippocampus. With exceptional specificity and stability, AtaGenix’s solutions empower researchers to explore tau pathology mechanisms and advance tau-targeted therapeutic development.
This study experimentally identifies shrimp plasma mesencephalic astrocyte-derived neurotrophic factor (MANF) as an LPS-induced protein that inhibits ERK phosphorylation and Dorsal expression in Litopenaeus vannamei hemocytes, elucidating its inflammation regulation mechanism via a conserved receptor tyrosine phosphatase (RPTP). AtaGenix supports the development of high-affinity antibodies, advancing research progress and providing new insights into the evolution of inflammation in invertebrates.
Contact Us
+86-27-87001869
info@atagenix.com
Building C, R & D Building, No. 666, Shendun 4th Road, Donghu New Technology Development Zone, Wuhan
